Market Access News | pharmaphorum

News

Mosquito is extracting blood from skin and has turned bright red

Takeda dengue vaccine receives positive CHMP opinion

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Takeda GmbH’s live, attenuated dengue tetravalent vaccine, Qdenga

News

Atara closes on first approval of transplant complication th...

Atara Biotherapeutics' cell therapy Ebvallo should be approved to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), according to the EMA's human med

News

Bayer get EU nod for extended use of contraceptive Mirena

Bayer's big-selling contraceptive Mirena has been approved in Europe to provide up to eight years of pregnancy protection, which the company says is the longest of any device of its kind.

News

US clears Omicron shots from Pfizer, Moderna for children

The US authorities have authorised use of two bivalent COVID-19 booster vaccines from Pfizer/BioNTech and Moderna – targeting the BA.4 and BA.5 subvariants of Omicron – for use in children

News

FDA sets Feb review date for Trodelvy in new breast cancer u...

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed b

News

Scotland backs three new uses for MSD's Keytruda

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent

Takeda dengue vaccine receives positive CHMP opinion

Atara closes on first approval of transplant complication th...

Bayer get EU nod for extended use of contraceptive Mirena

US clears Omicron shots from Pfizer, Moderna for children

FDA sets Feb review date for Trodelvy in new breast cancer u...

Scotland backs three new uses for MSD's Keytruda

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks